Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 9OTHER 1INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 7Barrett Esophagus 5Carcinoma, Hepatocellular 3Breast Neoplasms 3Multiple Myeloma 2Lymphoma, Follicular 2Lipoma 2Leiomyoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma in Situ 2Warts 1Vaginosis, Bacterial 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Syphilis 1Sexually Transmitted Diseases 1Retroperitoneal liposarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pilonidal Sinus 1Papillomavirus Infections 1Overweight 1Ovarian Neoplasms 1Osteosarcoma 1Obesity 1Neutropenia 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Myasthenia Gravis 1Melanoma 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDIV × Interventional × Advanced Solid Cancer × Clear all
NCT07123415 2025-11-19

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Aptabio Therapeutics, Inc.

Phase 1 Recruiting
110 enrolled
Other solid neoplasm

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡